Percutaneous delivery of oncogel for targeted liver tumor ablation and controlled release of therapeutics

Basit Öğe Kaydı
dc.authorscopusidŞeyda Gündüz / 53879546000
dc.authorwosidŞeyda Gündüz / FCD-5483-2022
dc.contributor.authorAlbadawi, Hassan
dc.contributor.authorZhang, Zefu
dc.contributor.authorKeum, Hyeongseop
dc.contributor.authorÇevik, Enes
dc.contributor.authorNagalo, Bolni M.
dc.contributor.authorGündüz, Şeyda
dc.contributor.authorKita, Hirohito
dc.contributor.authorOklu, Rahmi
dc.date.accessioned2025-04-18T10:13:30Z
dc.date.available2025-04-18T10:13:30Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, İSÜ Hastaneleri
dc.description.abstractAdvanced-stage liver cancers are associated with poor prognosis and have limited treatment options, often leading the patient to hospice care. Percutaneous intratumoral injection of anticancer agents has emerged as a potential alternative to systemic therapy to overcome tumor barriers, increase bioavailability, potentiate immunotherapy, and avoid systemic toxicity, which advanced-stage cancer patients cannot tolerate. Here, an injectable OncoGel (OG) comprising of a nanocomposite hydrogel loaded with an ionic liquid (IL) is developed for achieving a predictable and uniform tumor ablation and long-term slow release of anticancer agents into the ablation zone. Rigorous mechanical, physiochemical, drug release, cytotoxicity experiments, and ex vivo human tissue testing identify an injectable version of the OG with bactericidal properties against highly resistant bacteria. Intratumoral injection of OG loaded with Nivolumab (Nivo) and doxorubicin (Dox) into highly malignant tumor models in mice, rats, and rabbits demonstrates enhanced survival and tumor regression associated with robust tissue ablation and drug distribution throughout the tumor. Mass cytometry and proteomic studies in a mouse model of colorectal cancer that often metastasizes to the liver indicate an enhanced anticancer immune response following the intratumoral injection of OG. OG may augment immunotherapy and potentially improve outcomes in liver cancer patients.
dc.description.sponsorshipMayo Clinic Christian Haub Family National Institutes of Health
dc.identifier.citationAlbadawi, H., Zhang, Z., Keum, H., Cevik, E., Nagalo, B. M., Gunduz, S., ... & Oklu, R. (2024). Percutaneous Delivery of Oncogel for Targeted Liver Tumor Ablation and Controlled Release of Therapeutics. Advanced Materials, 36(45), 2406080.
dc.identifier.doi10.1002/adma.202406080
dc.identifier.endpage20
dc.identifier.issn09359648
dc.identifier.issue45
dc.identifier.pmid39148179
dc.identifier.scopus2-s2.0-85201148639
dc.identifier.scopusqualityQ1
dc.identifier.startpage1
dc.identifier.urihttp://dx.doi.org/10.1002/adma.202406080
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6996
dc.identifier.volume36
dc.identifier.wosWOS:001290952600001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorGündüz, Şeyda
dc.language.isoen
dc.publisherJohn wiley and sons inc
dc.relation.ispartofAdvanced materials
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAblation
dc.subjectBiomaterial
dc.subjectDrug Delivery
dc.subjectIntratumoral
dc.subjectLiver Cancer
dc.titlePercutaneous delivery of oncogel for targeted liver tumor ablation and controlled release of therapeutics
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Advanced Materials - 2024 - Albadawi - Percutaneous Delivery of Oncogel for Targeted Liver Tumor Ablation and Controlled.pdf
Boyut:
7.85 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

İSÜ Hastaneleri Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu